瑞舒伐他汀联合替格瑞洛治疗不稳定型心绞痛的临床效果研究

目的探究瑞舒伐他汀联合替格瑞洛治疗不稳定型心绞痛的临床疗效。方法 80例不稳定型心绞痛患者,随机分为实验组和参照组,各40例。参照组患者给予硫酸氢氯吡格雷片联合阿托伐他汀治疗,实验组患者给予瑞舒伐他汀联合替格瑞洛治疗。比较两组治疗效果、不良反应发生情况及治疗前后血脂指标总胆固醇(TC)、超敏C反应蛋白(hs-CRP)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)]。结果实验组治疗总有效率为95.0%,高于参照组的72.5%,差异有统计学意义(P<0.05)。治疗后,实验组TC(3.09±0.14)mmol/L、hs-CRP(4.26±1.31)mg/L、LDL-C(2.56±0.28)mmol/L及TG(2.08±0.13)mmol/L均低于参照组的(3.85±0.21)mmol/L、(6.18±1.42)mg/L、(2.75±0.24)mmol/L、(2.84±0.24)mmol/L,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论瑞舒伐他汀联合替格瑞洛治疗不稳定型心绞痛的临床疗效确切,可有效改善血脂水平,有助于患者预后恢复,此治疗方案可供临床采纳。

Clinical effect of rosuvastatin combined with ticagrelor in the treatment of unstable angina pectoris

Objective To investigate the clinical efficacy of rosuvastatin combined with ticagrelor in the treatment of unstable angina pectoris. Methods A total of 80 patients with unstable angina were randomly divided into experimental group and reference group, each with 40 cases. Patients in the reference group were treated with clopidogrel bisulfate tablets and atorvastatin, and patients in the experimental group were treated with rosuvastatin and ticagrelor. Both groups were compared in terms of therapeutic effects, occurrence of adverse reactions and blood lipid indexes otal cholesterol(TC), high-sensitivity C-reactive protein(hs-CRP), low-density lipoprotein cholesterol(LDL-C), triglycerides(TG)] before and after treatment. Results The total effective rate of treatment in the experimental group was 95.0%, which was higher than 72.5% in the reference group, and the difference was statistically significant(P<0.05). After treatment, the TC(3.09±0.14) mmol/L, hs-CRP(4.26±1.31) mg/L,LDL-C(2.56±0.28) mmol/L and TG(2.08±0.13) mmol/L of the experimental group were all lower than(3.85±0.21) mmol/L,(6.18±1.42) mg/L,(2.75±0.24) mmol/L, and(2.84±0.24) mmol/L of the reference group,and the difference was statistically significant(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion The combination of rosuvastatin and ticagrelor has a definite clinical efficacy in the treatment of unstable angina pectoris, which can effectively improve the level of blood lipid, and help the prognosis of patients to recover. This treatment plan can be adopted clinically.